PEOX-based Polymer Encapsulated Paclitaxel FID-007

DRUG2 trials

Sponsors

University of Southern California

Conditions

Advanced Malignant Solid NeoplasmHead and Neck Squamous Cell CarcinomaRefractory Malignant Solid Neoplasm

Phase 1

FID-007 in Treating Participants With Advanced Solid Tumors

Active, not recruitingNCT03537690

University of Southern CaliforniaAdvanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm

Start: 2018-05-25End: 2027-05-25Updated: 2025-08-12

FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer

TerminatedNCT06338657

University of Southern CaliforniaHead and Neck Squamous Cell Carcinoma

Start: 2024-04-01End: 2025-09-09Updated: 2025-09-16

Related Papers

Efficacy from the phase 1 study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with head and neck squamous cell carcinoma.

Journal of Clinical Oncology2024-06-011 citations

782-B FID-007: nanoencapsulated paclitaxel derived from a novel nano-drug delivery platform

2023-10-31

222-A The beacon® optofluidic system enables multi-functional characterization of T cells and sequential recovery of single cells from co-culture for downstream transcriptomic analysis

2023-10-31

A phase 1 dose escalation/expansion study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with solid tumors.

Journal of Clinical Oncology2023-06-01

A phase 1 trial of FID-007, a novel nanoparticle paclitaxel formulation, in patients with solid tumors.

Journal of Clinical Oncology2021-05-203 citations